Loading...
•
Sep 30
Rockwell Medical Q3 2025 Earnings Report
Estimated Revenue:$16.5M
-39.1% YoY
Estimated EPS:-$0.05
587.8% YoY
Key Takeaways
Rockwell Medical's Q3 2025 results showed revenue decline due to customer transition, but the company achieved profitability on an adjusted EBITDA basis and improved cash position.
Revenue for Q3 2025 was $15.9 million, down significantly year-over-year due to customer loss.
Net loss for the quarter was $1.8 million, compared to net income of $1.7 million a year ago.
Adjusted EBITDA was positive at $50,000, reflecting operational improvements.
Cash position increased to $23.7 million from $18.4 million in Q2 2025.
Rockwell Medical
Rockwell Medical
Forward Guidance
Rockwell Medical reaffirmed full-year 2025 guidance with sales between $65M–$70M and positive or near break-even adjusted EBITDA.
Positive Outlook
- 2025 net sales guidance confirmed at $65M–$70M
- Gross margin expected between 16%–18% for FY25
- Adjusted EBITDA forecasted between -$0.5M and +$0.5M
- Over 80% of customers are under long-term contracts
- New multi-year agreements signed with hospital and dialysis networks
Challenges Ahead
- Loss of largest customer impacted Q3 revenue and margins
- Year-over-year net sales fell 44% in Q3 2025
- Gross margin declined to 14%, down from 22% in Q3 2024
- Operating income turned negative compared to last year
- Adjusted EBITDA significantly lower than prior year’s $2.8M
Loading...
Key Statistics
Market Cap
$36.4M
P/E Ratio
13.59
Sector
Health Technology
Industry
Medical Specialties
52-Week High
$2.31
52-Week Low
$0.777
Gross Margin
14%
Adjusted EBITDA
$50K